Category Archives: Press Releases

John Theurer Cancer Center/RCCA collaborate with GTC to internalize proprietary NGS DNA and RNA testing

John Theurer Cancer Center/RCCA collaborate with GTC to internalize proprietary NGS DNA and RNA testing

John Theurer Cancer Center to Establish Next Generation Sequencing Laboratory for Precision Genomic Profiling of Cancers, Adapting Testing Developed for DNA and RNA IRVINE, Calif. and Hackensack, NJ, [May 27th, 2020] John Theurer Cancer Center (JTCC), at Hackensack Meridian Health Hackensack University Medical Center in New Jersey, and Genomic Testing Cooperative (GTC), Irvine, CA, announced today an agreement to establish a state-of-the-art, next generation sequencing (NGS) laboratory for molecular profiling . This NGS laboratory, located at John Theurer Cancer Center, will serve all physicians within Regional Cancer Care Associates (RCCA), a network of cancer care professionals in New Jersey, Connecticut, and Maryland. As a leading cancer institute and a member […]

GTC research is being presented at ASCO 2020

GTC research is being presented at ASCO 2020

GTC research is being presented at ASCO 2020 in the following three abstracts. 1. FGFR expression, fusion and mutation as detected by NGS sequencing of DNA and RNA. * 2. Measuring PD-L1 mRNA expression using targeted next generation sequencing and correlation with interferon pathway activation genes in lung and colorectal cancers. * 3. Bimodal ntrk expression and correlation with activation of PI3K/AKT pathway in lung cancer. * *Authors: Wanlong Ma, Ivan De Dios, Spiraggelos Antzoulatos, Jeffrey Estella, Maher Albitar; Genomic Testing Cooperative, Irvine, CA

New Collaboration to Offer Liquid Biopsy Testing

New Collaboration to Offer Liquid Biopsy Testing

Genomic Testing Cooperative (GTC) and C2i Genomics Announce Collaboration to Offer Liquid Biopsy Testing for Staging and Monitoring Solid Tumors Based on Pattern Recognition of Whole Genome DNA Signature IRVINE, Calif. and NEW YORK, Jan. 14, 2020 /PRNewswire/ — Genomic Testing Cooperative, LCA (GTC), a cooperative (Co-Op) company offering comprehensive genomic profiling of hematologic and solid tumors, and C2i Genomics, Inc, a tumor pattern recognition liquid biopsy company, today announced collaboration to develop liquid biopsy tests for the staging and monitoring of solid tumors.  C2i Genomics approach is based on proprietary technology using AI-based pattern recognition of whole genome sequencing of cell-free DNA (cfDNA).  The technology will be adapted by GTC […]

Genomic Testing Cooperative (GTC) Receives Medicare (Palmetto GBA) Coverage for GTC-Solid Tumor Profile (434 gene) Test

Genomic Testing Cooperative (GTC) Receives Medicare (Palmetto GBA) Coverage for GTC-Solid Tumor Profile (434 gene) Test

GTC Solid Tumor Profile™ with 434 genes test is now covered by Medicare for patients with a wide range of solid tumor cancers Irvine, California– January 7, 2020 – Genomic Testing Cooperative, LCA announced that the Medicare Administrative Contractor Palmetto GBA (MolDx®) has established coverage for its solid tumor molecular profile. The GTC-Solid Tumor Profile provides a comprehensive evaluation of the abnormalities in the entire coding sequence of 434 genes in various types of solid tumors. This decision of covering solid tumors along with the previous coverage decision of two GTC hematology profiles allows GTC to offer comprehensive genomic profiling with next-generation sequencing (NGS) for patients with all types of […]

Genomic Testing Cooperative to Present at American Society of Hematology Annual Meeting 2019

Genomic Testing Cooperative to Present at American Society of Hematology Annual Meeting 2019

Genomic Testing Cooperative to Present Data on its Proprietary RNA Profiling and Artificial Intelligence Algorithms at American Society of Hematology Annual Meeting Irvine, California– December 3, 2019 – Genomic Testing Cooperative, LCA (GTC) announced that they will be presenting data on their proprietary AI-based algorithms and RNA and DNA testing at the American Association of Hematology (ASH) annual meeting. In collaboration with multiple academic centers, GTC developed new approaches for the classification of diseases and prediction of response to combination therapy. Dr. Maher Albitar, GTC Chief Executive Officer and Chief Medical Officer, stated “Cancer is complex disease and requires complex biomarkers for predicting its behavior. RNA Sequencing provides a wealth […]

Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome (MDS)

MDS is defined as ineffective hematopoiesis characterized by adequate or increased hematologic elements in bone marrow with peripheral cytopenia. Therefore, the presence of cytopenia in one or more hematologic lines is necessary for the diagnosis of MDS. However, numerous reactive conditions other than MDS can cause cytopenia and these conditions must be distinguished from MDS. While dysplasia in hematologic cells is an indication of the diagnosis of MDS, the presence of mutations along with cytopenia is the most conclusive evidence for the diagnosis of MDS. Normal individuals above the age of 50 may show mutation in some genes (ASXL1, TET2, DNMT3, and TP53), however, the level (Variant allele frequency, VAF) […]

Genomic Testing Cooperative Receives Medicare (Palmetto GBA) Coverage for two NGS Hematology Molecular Profiling Tests Including Liquid Biopsy for Hematologic Neoplasms

Genomic Testing Cooperative Receives Medicare (Palmetto GBA) Coverage for two NGS Hematology Molecular Profiling Tests Including Liquid Biopsy for Hematologic Neoplasms

GTC Receives Medicare Coverage for 2 NGS Hematology Molecular Profiling Tests Including Liquid Biopsy for Hematologic Neoplasms Irvine, California– June 19, 2019 – Genomic Testing Cooperative, LCA announced that the Medicare Administrative Contractor Palmetto GBA (MolDx®) has finalized its review and has established coverage for two Genomic Testing Cooperative (GTC) hematology profiles: GTC-Hematology (177 gene DNA profiling) and GTC-Hematology Plus (177 gene DNA and 1408 gene RNA profiling). The two Comprehensive Genomic Profile (CGP) tests are designed to help Pathologists and Hematologists/Oncologists in establishing the precise diagnosis, prognosis and determine therapy in hematologic neoplasms. The GTC Hematology test (177 gene DNA Profile) can be performed on cell-free DNA (cf-DNA) from […]

Before you go...Let's stay in touch!
Subscribe on our list

- Get the Latest News
- Get Notified on upcoming events

* Your email is safe with us. We hate spamming, as much as you do!